Drugs / IVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05882357 | Jun 2023 → Sep 2025 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05882357 ↗ |
| Route | Oral | “Granules for oral administration” NCT05882357 ↗ |